A persistent gap remains between what Annex 1 requires and what facilities can demonstrate. Let's take a closer look at four common compliance failures.
- Use Of AI In FDA Inspection Activities: Strategies For Effective Preparation
- A Comparison Of 6 Analytical Validation Guidelines Using Data Envelopment Analysis
- Affinity Membranes Are Moving Closer To Commercial Reality
- AI Has Arrived In Biotech CMC Amid Patchwork Governance
- Avoiding Common Pitfalls In CDMO–Sponsor Relationships Through Integrated Execution Models
- The Future Of Continuous Is Integrated Manufacturing: The 4 Misconceptions About A Lean Process
- CDMO Selection: Start With The Relationship, Not The RFP
GUEST COLUMNISTS
-
Use Of AI In FDA Inspection Activities: Strategies For Effective Preparation
Are you ready? FDA has begun to implement the use of artificial intelligence in its operations, particularly during inspection activities.
-
A Comparison Of 6 Analytical Validation Guidelines Using Data Envelopment Analysis
This is the first published application of data envelopment analysis to six major pharmaceutical analytical validation guidelines, including ICH Q2(R2), USP, ChP, and Brazil's ANVISA.
-
Affinity Membranes Are Moving Closer To Commercial Reality
A recent review shows advances in surface chemistry and ligand engineering are moving the needle for next-generation affinity membranes.
-
AI Has Arrived In Biotech CMC Amid Patchwork Governance
AI is surfacing within regulatory and CMC workflows at a vigorous pace. Unfortunately, in small and midsize biotechs, it's happening faster than governance can keep up.
-
Avoiding Common Pitfalls In CDMO–Sponsor Relationships Through Integrated Execution Models
Let's delve into the key pitfalls to avoid when working with a CDMO and the integrated execution model that solves or mitigates these pitfalls before they occur.
-
The Future Of Continuous Is Integrated Manufacturing: The 4 Misconceptions About A Lean Process
Pharmaceutical continuous manufacturing is an enabler of better manufacturing, but only when implemented with intention.
-
CDMO Selection: Start With The Relationship, Not The RFP
Friction often comes from unspoken expectations. Before production begins, treat the combined sponsor-CDMO group as one extended team and intentionally make “how we work together” visible.
BIOSIMILAR WHITE PAPERS
-
Regulatory Considerations For Excipients Used In Lipid Nanoparticles
Review the regulatory classification of LNPs, liposomes, and novel excipients as well as specific requirements outlined in regulatory guidance documents and strategies to navigate emerging challenges.
-
Biopharma Supply, Reimagined: Regional, Resilient Manufacturing4/1/2026
Persistent disruption is redefining biopharma supply chains. Explore how regional manufacturing, integrated risk management, and closer collaboration help build resilience and improve agility.
-
Why Choose Robotic Processing For Small Batch Aseptic Filling1/9/2026
Reducing human intervention in aseptic filling is critical for safety and cost efficiency. Learn why automation is essential for small-batch applications and how it’s transforming sterile drug manufacturing.
-
ADC Development Grows More Complex — SPR Insights Bring Clarity4/14/2026
Explore how real-time kinetic analysis reveals how conjugation, linker chemistry, and drug loading influence antibody–antigen interactions, while enabling sensitive detection of anti-drug antibodies.
-
ADC Manufacturing: Practices, Challenges, And The Road Ahead6/15/2026
ADCs are advancing quickly, but manufacturing complexity is rising just as fast. Key challenges in scale-up, regulation, and costs are reshaping how the next generation of therapies will be delivered.
-
Bio-Based Polymers Towards Net Zero In Single-Use Bioprocessing6/13/2025
Decarbonizing healthcare and pharmaceuticals is vital to meet climate goals and safeguard public health. Learn why these energy-intensive sectors must act swiftly to reduce emissions and navigate complex global supply chains.
BIOSIMILAR APP NOTES & CASE STUDIES
- Comparing Process Development Approaches For Recombinant Proteins
- Integrated Services For Cell Line Preparation And Storage
- Performance Of Mobius® Bag Assemblies With Ultimus® Film In Truck Shipping Simulation Test
- A Sustainable Future: Phasing Out Animal Testing
- Production Of A Highly Concentrated Monoclonal Antibody
BIOSIMILAR DEVELOPMENT CONTENT COLLECTIONS
The debate over whether the biosimilar regulatory paradigm can shift away from comparative efficacy trials has intensified over the past few years. This collection of articles serves as a snapshot of the many different components of this ongoing discussion.
More Content CollectionsBIOSIMILAR DEVELOPMENT NEWS
- Organon Canada And Henlius Expand Access To Denosumab Treatments With Launch Of BILDYOS (denosumab injection) And TUZEMTY (denosumab injection), Biosimilars To PROLIA And XGEVA
- Organon And Samsung Bioepis Expand Agreement To Commercialize PYZCHIVA (ustekinumab), A Biosimilar Referencing STELARA (ustekinumab) In Canada
- AAM Applauds Momentum As Two Bills Move Through Senate HELP Committee
- Sandoz Steps Up In-House Biosimilar Capabilities, Opening State-Of-The-Art Development Centre To Capture 'Golden Decade' Opportunity
- Alvotech Announces FDA Acceptance Of Biologics License Application For AVT16, A Proposed Interchangeable Biosimilar To Entyvio®
- Xbrane Biopharma AB And JOINN Biologics US Inc. Enter Strategic Partnership To Develop Xdarzane – Xbrane´s Biosimilar Candidate To Darzalex (Daratumumab)
- Abbott Receives Approval For Two New Biosimilars In Brazil, Expanding Access To Treatment For Osteoporosis And Bone Complications Related To Cancer
- Organon Secures US Food And Drug Administration Approval Expanding Indications For TOFIDENCE (tocilizumab-bavi) In Cytokine Release Syndrome (CRS) And Pediatric COVID-19
NEWSLETTER ARCHIVE
- 06.18.26 -- Reduce mAb Aggregates: Practical Strategies
- 06.18.26 -- Will FDA's One-Day Inspection Pilot Stand The Test Of Time?
- 06.11.26 -- Process Intensification: Your Guide To "Doing More With Less"
- 06.04.26 -- Are Biotechs Wasting Time On The Wrong CDMO?
- 05.21.26 -- Minimizing Regulatory Risk For Biologics Manufacturing Changes